Pre-Galien Forum Addresses Drug Pricing and Access in the Trump Administration—And the Awards Gala Draws an Influential Crowd Eager to Join the Festivities

Prix Galien 2017 USA Forum convened in New York City, where key healthcare innovation leaders gathered to discuss trending health challenges. Organized by the Galien Foundation, with support from Finn Partners, the Forum and the Prix Galien combine the intensity of Davos with the excitement of the Nobel Prize for achievements that can change the human condition.

During the Forum keynote, top pharma executives discussed drug pricing and access through the lens of the Trump Administration. The exchange centered on how there is not a “one size fits all” approach to the pricing problem and how to chart a path forward. Panelists grappled with the challenge on how to measure success—patient care or business priorities. The pendulum now swings toward “how does a drug impact patient lives.”

The panelists touched on fair market versus fair profit. Executives acknowledged the need to shift the health ecosystem to operate under the indication-based reimbursement model, where the price of a drug correlates to how well it works.

The discussion concluded with panelists reiterating that there is not just one approach to the pricing conundrum—nor is one sector able to fix this alone. Patients, physicians, providers, payers, and policymakers must work together to find a solution.

While that was the big news coming out of the forum, the Prix Galien Awards Gala had it’s own special panache, attended by numerous Nobel Laureates who gathered to honor and celebrate the industry’s best. These gala photos paint a picture of an industry star-studded night.

From left to right: P. Roy Vagelos, MD, Chairman, Regeneron Pharmaceuticals, Retired Chairman and Chief Executive Officer, Merck & Co., Inc; Leonard Schleifer, MD, PhD, Founder, President and CEO, Regeneron Pharmaceuticals; Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center; Steve Pearson, MD, Founder and President, Institute for Clinical and Economic Review (ICER); and Steve Miller, MD, Senior Vice President and Chief Medical Officer, Express Scripts lead the discussion on drug pricing.
Prix Galien award winners and attendees were feted with a special dinner in the Blue Whale room at NYC’s American Museum of Natural History.
Industry giant, Dr. P. Roy Vagelos presents the “Winner of Best Medical Technology” to INSIGHTEC for Exablate Neuro, the first focused ultrasound device approved by the FDA to treat essential tremor patients with non-invasive MR-guided focused ultrasound thalamotomy.
“Winner of Best Biotechnology Product”: Biogen and Ionis Pharmaceuticals for SPINRAZA®, treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
“Winner of Best Pharmaceutical Product”: AbbVie and Genentech (a Member of the Roche Group) for Venclexta™, a treatment for people diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least one prior treatment.

Ads

You May Also Like

Healthcare Highlights

LABEL CHANGES Over-the-counter medication labels contain a seemingly infinite amount of microscopic words that ...

Industry Briefs

GOOGLE DRUG ADS Last month, Google set aside $500 million to potentially settle a ...

Prostate Cancer

“Each year more patients present with prostate cancer at increasingly younger ages and with ...